Disease details

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

5 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02677077 (ClinicalTrials.gov)	December 31, 2015	3/12/2015	Clinical Disease Activity With Long Term Natalizumab Treatment	MRI and Clinical Disease Activity in Patients Treated Long Term With Natalizumab	Relapsing-Remitting Multiple Sclerosis	Drug: natalizumab	Biogen	NULL	Completed	18 Years	65 Years	All	277		Belgium;Czechia;Czech Republic
2	NCT01144052 (ClinicalTrials.gov)	June 2010	11/6/2010	Natalizumab De-escalation With Interferon Beta-1b	De-escalation After Natalizumab Treatment With Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis	Relapsing-remitting Multiple Sclerosis	Drug: interferon beta -1b;Drug: Natalizumab	Claudio Gobbi	Ospedale Civico, Lugano	Completed	18 Years	60 Years	All	19	Phase 4	Switzerland
3	EUCTR2009-017490-38-DE (EUCTR)	03/05/2010	01/02/2010	Randomized Treatment Interruption of Natalizumab - RESTORE	Randomized Treatment Interruption of Natalizumab - RESTORE	Natalizumab is a highly efficacious therapy used in the treatment of patients with relapsing multiple sclerosis (MS).This is a prospective randomized study in subjects with relapsing forms of MS who have been receiving natalizumab treatment for at least 12 months with no MS relapses during these 12 months. MedDRA version: 12.1;Level: LLT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis	Trade Name: Tysabri INN or Proposed INN: NATALIZUMAB Other descriptive name: TYSABRI Trade Name: Copaxone INN or Proposed INN: GLATIRAMER ACETATE Other descriptive name: COPAXONE Trade Name: AVONEX INN or Proposed INN: INTERFERON BETA -1A Other descriptive name: AVONEX Trade Name: Urbason Forte INN or Proposed INN: METHYLPREDNISOLONE Other descriptive name: URBASON FORTE	Biogen Idec	NULL	Not Recruiting			Female: yes Male: yes	200		Germany;Spain
4	NCT01077466 (ClinicalTrials.gov)	March 2010	26/2/2010	Natalizumab Treatment of Progressive Multiple Sclerosis	Natalizumab Treatment of Progressive Multiple Sclerosis	Primary Progressive Multiple Sclerosis;Secondary Progressive Multiple Sclerosis	Drug: Natalizumab	Rigshospitalet, Denmark	Copenhagen University Hospital, Hvidovre;Biogen Idec;University of Copenhagen;Signifikans ApS	Completed	19 Years	55 Years	Both	24	Phase 2	Denmark
5	NCT00424788 (ClinicalTrials.gov)	January 2007	18/1/2007	A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)	A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)	Relapsing Forms of Multiple Sclerosis	Procedure: Plasma exchange;Drug: natalizumab treatment	Biogen Idec	NULL	Completed	18 Years	50 Years	Both	12	Phase 0	United States

先頭へ